Method, device, and kit for maintaining physiological levels of steroid hormone in a subject

• US 20100022487A1
• Filed: 07/24/2008
• Published: 01/28/2010
• Est. Priority Date: 07/24/2008
• Status: Abandoned Application

• Current Assignee: Searete LLC (Intellectual Ventures LLC)
• Original Assignee: Searete LLC (Intellectual Ventures LLC)
• Inventors: Ishikawa, Muriel Y., Wood, Lowell L. JR., Rivet, Dennis J., Hyde, Roderick A., Sweeney, Elizabeth A., Wood, Victoria Y.H.
• Application Number:
  US12/220,708
• Publication Number:
  US 20100022487A1
• Time in Patent Office: Days
• US Class Current: 514/170
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61P 5/00 Drugs for disorders of the endocrine system
• CPC Class Codes: A61P 5/24 of the sex hormones
• CPC Class Codes: G16H 20/10 relating to drugs or medications, e.g. for ensuring correct administration to patients

Abstract

A method, device, or kit is provided which maintain a substantially physiological cyclic pre-menopausal level of one or more steroid hormones in a mammalian subject in need thereof. The method, device, or kit includes providing to the subject at least one treatment regimen including replacement therapy for the one or more steroid hormones or metabolites or modulators thereof, wherein the at least one treatment regimen is determined based on pre-menopausal cyclic steroid hormone levels of the subject and on current cyclic steroid hormone levels of the subject, wherein the at least one treatment regimen is configured to maintain the subject'"'"'s one or more steroid hormones or metabolites or modulators thereof at substantially physiological cyclic pre-menopausal levels. The method, device, or kit can be used for the treatment of a disease or condition in the mammalian subject.

Claims

1. A method for maintaining a substantially physiological cyclic pre-menopausal level of one or more steroid hormones in a mammalian subject in need thereof comprising:

providing to the subject at least one treatment regimen including replacement therapy for the one or more steroid hormones or metabolites or modulators thereof, wherein the at least one treatment regimen is determined based on pre-menopausal cyclic steroid hormone levels of the subject and on current cyclic steroid hormone levels of the subject.

2. The method of claim 1, wherein the at least one treatment regimen is configured to maintain the subject'"'"'s one or more steroid hormones or metabolites or modulators thereof at substantially physiological cyclic pre-menopausal levels.

3. The method of claim 1, wherein the current cyclic steroid hormone levels are based on one or more of peri-menopausal, early menopausal, late menopausal, or post-menopausal steroid hormone levels of the subject.

4. The method of claim 1, further comprising determining the one or more steroid hormones levels in the subject during a treatment period.

5. The method of claim 4, wherein the treatment period includes a time period preceding treatment or a time period during treatment with the at least one treatment regimen.

6. The method of claim 4, wherein the determining the one or more steroid hormones levels occurs at multiple time points during the treatment period.

7. The method of claim 4, further comprising providing to the subject at least one second treatment regimen adjusted to maintain the subject'"'"'s one or more steroid hormones or one or more metabolites or modulators thereof at substantially physiological cyclic pre-menopausal levels.

8. The method of claim 1, wherein the at least one treatment regimen is determined based at least in part on a time-history of serum steroid hormone levels in the subject, on inferred peak values or minimal values of serum steroid hormone levels in the subject, on age of the subject, or on categorization relative to profiles of patient populations.

9. The method of claim 1, wherein the at least one treatment regimen is determined based at least in part on Fourier analysis of the cyclic steroid hormone levels in the subject, or on harmonic analysis of the cyclic steroid hormone levels in the subject.

10. The method of claim 1, wherein the at least one treatment regimen is determined based on a genetic profile of the subject.

12. The method of claim 1, wherein the at least one treatment regimen is determined based at least in part on scaled values of the pre-menopausal cyclic steroid hormone levels in the subject.

13. The method of claim 12, wherein the at least one treatment regimen is determined based at least in part on a scaled value approximately equal to one.

14. The method of claim 12, wherein the at least one treatment regimen is determined based at least in part on a scaled value dependent on age of the subject.

15. The method of claim 1, wherein the subject is peri-menopausal, early menopausal, late menopausal, or post menopausal.

16. The method of claim 1, further comprising determining the subject'"'"'s one or more steroid hormones levels when the subject is premenopausal and has no underlying condition affecting production of steroid hormones.

17. The method of claim 16, wherein the at least one treatment regimen is determined based at least in part on a time-history of serum steroid hormone levels in the subject, on inferred peak values or minimal values of serum steroid hormone levels in the subject, on age of the subject, or on categorization relative to profiles of patient populations.

18. The method of claim 16, wherein the at least one treatment regimen is determined based on a genetic profile of the subject.

20. The method of claim 1, wherein the at least one treatment regimen is determined while the subject is not pre-menopausal.

21. The method of claim 1, wherein the at least one treatment regimen is determined while the subject has an underlying condition affecting production of hormones.

22. The method of claim 21, wherein the subject has undergone oopherectomy, and the at least one treatment regimen is determined based on the subject'"'"'s pre-surgical cyclic steroid hormone levels.

26. The method of claim 1, wherein the hormones or their metabolically related compounds are sterols, androgens, testosterone progestogens, estrogens, estradiol, estrone, follicle-stimulating hormone, luteinizing hormone, inhibin B, anti-Mullerian hormone thyroid-related hormones, or analogs or derivatives thereof.

29. The method of claim 1, wherein the at least one treatment regimen is determined based at least in part on one or more ratios of levels of the steroid hormones or metabolically related compounds in the subject, and the treatment regimen restores the one or more ratios to physiological cyclic pre-menopausal levels.

30. The method of claim 29, wherein the one or more ratios include a ratio of different estradiols, an estradiol to an estrone, or a testosterone to an estrogen.

31. The method of claim 29, wherein the one or more ratios include a ratio of the one or more steroid hormones or metabolically related compounds at different time intervals of the cycle in the subject.

32. The method of claim 1, further comprising determining one or more ratios of levels of the steroid hormones or metabolically related compounds in the subject.

33. The method of claim 1, wherein the at least one treatment regimen is determined based on the subject'"'"'s pre-menopausal cyclic levels of one or more steroid hormone receptors and on the subject'"'"'s current levels of the one or more steroid hormone receptors.

34. The method of claim 33, wherein the one or more hormone receptors is an estrogen receptor.

35. The method of claim 1, wherein the at least one treatment regimen is based on diagnostic data.

40. The method of claim 1, wherein the at least one treatment regimen is determined using an algorithm designed to determine a dosage of the one or more steroid hormones or metabolites, modulators, or analogs thereof in the at least one treatment regimen.

41. The method of claim 1, wherein the subject'"'"'s pre-menopausal cyclic steroid hormone levels or one or more of the subject'"'"'s peri-menopausal, early menopausal, late menopausal, or post-menopausal steroid hormone levels are determined for a period of time from at lease approximately 7 days to approximately 168 days.

110. The method of claim 1, further comprising determining cyclic pre-menopausal levels of the one or more steroid hormones in the subject.

11. (canceled)

19. (canceled)

23-25. -25. (canceled)

27-28. -28. (canceled)

36-39. -39. (canceled)

42-63. -63. (canceled)

64. A method for restoring a physiological level of one or more steroid hormones in a mammalian subject comprising:

providing to the subject at least one treatment regimen including replacement therapy for the one or more steroid hormones or metabolites or modulators thereof, wherein the at least one treatment regimen is determined based on the subject'"'"'s pre-menopausal cyclic steroid hormone levels and on current cyclic steroid hormone levels in the subject.

65. The method of claim 64, wherein the at least one treatment regimen is configured to maintain the subject'"'"'s one or more steroid hormones or metabolites or modulators thereof at substantially physiological cyclic pre-menopausal levels.

66. The method of claim 64, wherein the current cyclic steroid hormone levels are based on one or more of peri-menopausal, early menopausal, late menopausal, or post-menopausal steroid hormone levels of the subject.

67. The method of claim 64, further comprising determining the one or more steroid hormones levels in the subject during a treatment period.

68. The method of claim 67, wherein the treatment period includes a time period preceding treatment or a time period during treatment with the at least one treatment regimen.

69. The method of claim 67, wherein the determining the one or more steroid hormones levels occurs at multiple time points during the treatment period.

70. The method of claim 67, further comprising providing to the subject at least one second treatment regimen adjusted to maintain the subject'"'"'s one or more steroid hormones or one or more metabolites or modulators thereof at substantially physiological cyclic pre-menopausal levels.

71. The method of claim 64, wherein the at least one treatment regimen is determined based at least in part on a time-history of serum steroid hormone levels in the subject, on inferred peak values or minimal values of serum steroid hormone levels in the subject, on age of the subject, or on categorization relative to profiles of patient populations.

72. The method of claim 64, wherein the at least one treatment regimen is determined based at least in part on Fourier analysis of the cyclic steroid hormone levels in the subject, or on harmonic analysis of the cyclic steroid hormone levels in the subject.

73. The method of claim 64, wherein the at least one treatment regimen is determined based on a genetic profile of the subject.

74. The method of claim 64, wherein the at least one treatment regimen is determined based at least in part on scaled values of the pre-menopausal cyclic steroid hormone levels in the subject.

75. The method of claim 74, wherein the at least one treatment regimen is determined based at least in part on a scaled value approximately equal to one.

76. The method of claim 74, wherein the at least one treatment regimen is determined based at least in part on a scaled value dependent on age of the subject.

78. The method of claim 64, further comprising determining the one or more steroid hormones levels in the subject when the subject is premenopausal and has no underlying condition affecting production of steroid hormones.

79. The method of claim 78, wherein the at least one treatment regimen is determined based on a previous time-history of serum steroid hormone levels in the subject, or on inferred peak values or minimal values of serum steroid hormone levels in the subject.

80. The method of claim 78, wherein the at least one treatment regimen is determined based on a genetic profile of the subject.

81. The method of claim 64, wherein the at least one treatment regimen is determined while the subject is not pre-menopausal.

82. The method of claim 64, wherein the at least one treatment regimen is determined while the subject has an underlying condition affecting production of hormones.

83. The method of claim 82, wherein the subject has undergone oopherectomy, and the at least one treatment regimen is determined based on pre-surgical cyclic steroid hormone levels in the subject.

90. The method of claim 64, wherein the at least one treatment regimen is determined based at least in part on one or more ratios of levels of the steroid hormones or metabolites or modulators thereof in the subject, and the treatment regimen restores the one or more ratios to physiological cyclic pre-menopausal levels.

91. The method of claim 90, wherein the one or more ratios include a ratio of different estradiols, an estradiol to an estrone, or a testosterone to an estrogen.

92. The method of claim 90, wherein the one or more ratios include a ratio of the one or more steroid hormones or metabolically related compounds at different time intervals of the cycle in the subject.

93. The method of claim 64, wherein the at least one treatment regimen is determined based on the subject'"'"'s pre-menopausal cyclic levels of one or more steroid hormone receptors and on the subject'"'"'s current levels of the one or more steroid hormone receptors.

100. The method of claim 64, wherein the at least one treatment regimen is determined using an algorithm designed to determine a dosage of the one or more steroid hormones or metabolites, modulators, or analogs thereof in the at least one treatment regimen.

101. The method of claim 64, wherein the subject'"'"'s pre-menopausal cyclic steroid hormone levels or the subject'"'"'s peri-menopausal or post-menopausal steroid hormone levels are determined for a period of time from approximately 7 days to approximately 168 days.

77. (canceled)

84-89. -89. (canceled)

94-99. -99. (canceled)

102. A kit comprising

at least one treatment regimen including one or more steroid hormones or metabolites, modulators, or analogs thereof providing varying dosages of the one or more steroid hormones or metabolites, modulators, or analogs thereof, the at least one treatment regimen based on the subject'"'"'s pre-menopausal cyclic steroid hormone levels and on current cyclic steroid hormone levels, and

instructions for administering the at least one treatment regimen and for monitoring the effectiveness of hormone replacement therapy in the menopausal subject.

103-109. -109. (canceled)